A peptide is the same molecule whether it comes out of a stocked vial or off a bench run started because you asked for it. What differs is everything around the molecule: who wrote the specification, when the material was made, how long you wait, and what evidence arrives with it. Choosing between a catalogue peptide and custom peptide synthesis usually turns on one question — does the documented material already match the experiment?
This guide sets out when stock is genuinely enough, which requirements only a made-to-order run can meet, what drives the quoted figure and the waiting time, and what documentation to insist on either way.
The short answer
- A catalogue peptide is stock; a custom peptide is made to your order. The useful test is not which route sounds more rigorous, but whether the documented sequence, form and quantity already on a shelf match the experiment.
- Standard published sequences are usually catalogue items. Where a listing is the right sequence in the right form with documentation matching the vial, a fresh synthesis adds time and expense without adding information.
- Custom synthesis exists for what stock cannot cover. Non-natural residues, site-specific modifications, labels, composition-matched control peptides, an unusual quantity, or acceptance criteria written by you rather than the maker.
- Sequence character drives the chemistry more than length alone. Mueller and colleagues describe how poorly solvated chains undergo “on resin aggregation”, which they say prevents complete deprotection and coupling steps.
- The purity target is a cost lever, not a free upgrade. De Luca and colleagues state that in batch chromatography “it is practically impossible to reach both a high purity and high yield at the same time”.
- The documentation question is identical on both routes. Identity, purity with its method, salt form and peptide content, and a lot number matching the vial. ICH Q7, a drug-manufacturing guideline, defines a specification as “a list of tests, references to analytical procedures, and appropriate acceptance criteria”.
Custom peptide synthesis
Made-to-order synthesis · bespoke peptide · a peptide built to a specification you wrote
- What it is
- A peptide assembled to order, to a sequence, form, quantity and acceptance criteria agreed before the run
- What a catalogue peptide is
- Material already made to the maker’s own specification and normally released against a lot-specific report
- What you can specify
- Sequence and termini, side-chain modifications, labels, salt form, scale, purity target, analytical package
- What a specification means
- ICH Q7 defines it as a list of tests, analytical procedures and acceptance criteria; that guideline covers drugs for human use, and this article makes no claim about which rules reach a laboratory reagent
- What drives the chemistry
- Residue count, aggregation-prone stretches, unusual building blocks and the purity target
- Underlying method
- Both routes normally use solid-phase synthesis; Behrendt and colleagues call Fmoc solid-phase peptide synthesis “the method of choice for peptide synthesis”
- What it is not
- Not a quality grade, not an assurance of higher purity, and not a substitute for evidence tied to the batch you receive
What choosing custom synthesis can settle
- Getting a sequence or form that nobody stocks
- Setting the quantity, salt form and acceptance criteria yourself
- Whether the finished material is purer than a documented stock lot
- Whether the peptide will behave as expected in your assay
The first two are what the route buys you. The second two are decided by the chemistry and the analysis, not by how the order was placed.
Two routes to the same molecule
Both routes end the same way: a sealed vial of freeze-dried powder with a label and a report. The chemistry underneath is usually the same, too. Since Merrifield published the solid-phase method in 1963, assembling a chain on resin has been the standard approach, and Behrendt, White and Offer open their review by calling Fmoc solid-phase synthesis “the method of choice for peptide synthesis”. A catalogue peptide is not made by a lesser process.
What differs is the order of events. On the catalogue route the material exists first and you select it: the maker chose the sequence, scale, salt form and purity target, and a report describes what resulted. On the custom route the decision comes first and the material follows. Waiting, pricing and the risk of a surprise all follow from that one difference.
| Question | Catalogue peptide | Custom synthesis |
|---|---|---|
| Who writes the specification | The maker, before you arrive | You, before the run starts |
| When it was made | Already made; a dated lot exists | After the order is confirmed |
| Sequence choice | Limited to what is listed | Whatever the chemistry supports |
| Modifications and labels | Only as offered on the listing | Specified by position and type |
| Quantity | Listed formats, subject to availability | Agreed at the outset |
| Waiting time | Dispatch and transit only | Scheduling, synthesis, purification, analysis |
| What the report describes | An existing lot, readable before you buy | A batch that does not yet exist |
| If it misses the mark | Visible in advance from the report | Settled by the criteria you agreed |
When a catalogue peptide is enough
Stock lists exist because some sequences are ordered often enough to be worth making in advance, and because the inputs are no longer exotic. Behrendt and colleagues note that high-quality Fmoc building blocks “are available at low cost because of the economies of scale” created by large-scale therapeutic peptide manufacture, and that many modified derivatives are sold ready-made. Scale is what makes a standing research peptide catalogue possible.
Four conditions together mean stock is the sensible answer. The sequence is a standard published one rather than an analogue of your own. The listed form is the form you need — the same termini, the same modifications or lack of them, the right salt, a single compound rather than a blend. The documentation for that lot answers your identity and purity questions before you spend anything. And what is listed can cover the quantity you need, ideally from one lot.
If all four hold, a bespoke run buys only delay. We sell catalogue research peptides, so read this as an interested party’s checklist and apply the same four tests to our listings as to anyone else’s.
Before commissioning a synthesis, check whether the sequence you need is already in our catalogue.
Browse the catalogueWhen custom peptide synthesis is the only option
A sequence or form that is not stocked anywhere
Novel analogues, species variants, fragments with defined termini, truncations built to test a hypothesis, cyclized versions of a linear peptide. If the molecule exists only in your plan, somebody has to make it.
Site-specific modifications and labels
Phosphorylation at a named residue, acetylation, C-terminal amidation, biotinylation, a fluorophore, a stable-isotope label. Quantitative proteomics is built on the last of these: Gerber and colleagues described synthesizing peptides “with incorporated stable isotopes as ideal internal standards”. Labels are not neutral: Hughes, Rawle and Boxer reported that water-soluble fluorophores “can interact strongly with lipid bilayers”, influencing how the labelled target behaves. A labelled peptide is a different molecule.
Matched control peptides
A credible experiment often needs a second peptide differing from the active one in a single, deliberate way. Cunningham and Wells set the pattern in 1989 with alanine-scanning mutagenesis, substituting alanine at every residue across three segments of human growth hormone. Composition-matched shuffled sequences are the other common case: Vadukul and colleagues note that many studies use reversed and scrambled forms of amyloid-β as control peptides. Neither is normally a stock item, which is why scrambled peptide controls are a common reason for a custom order.
A quantity or specification of your own
A defined mass from one batch, a particular salt form, or acceptance criteria tighter than the maker’s standard release. This is a purchasing requirement rather than a chemistry one, and an existing lot may well satisfy it.
What actually drives cost and lead time
A quoted figure follows the specification behind it, so comparing two without reading what each one covers tells you little. Four things move the number.
Residue count. Each residue is another round of coupling and deprotection, and the fraction of chains surviving every round intact falls as the chain lengthens. Our guide to solid-phase peptide synthesis works through that arithmetic.
Sequence character. Length alone is a poor predictor. Some sequences associate on the resin and resist the chemistry: Mueller and colleagues describe “on resin aggregation” in chains containing β-sheets or α-helices, which they say prevents complete deprotection and coupling steps, and they cite a reported 4% yield for a hydrophobic 34-residue fragment made in dimethylformamide, which rose to 12% when the solvent was changed. These sequences have a literature of their own: Paradís-Bas and colleagues titled their 2016 review “The road to the synthesis of difficult peptides”.
Building blocks and modifications. Routine derivatives are inexpensive because they are made in bulk. An unusual residue or a non-standard label adds expense, and may need development rather than execution.
The purity target. This is the lever most often pulled without thinking. De Luca and colleagues put it plainly: in batch chromatography “it is practically impossible to reach both a high purity and high yield at the same time”. A narrower collection window raises purity and discards product, and impurities “may differ from the target peptide by a single amino acid” — the hardest neighbours to separate. The same review cites an estimate putting 50 to 70% of manufacturing expenditure in downstream processing, so a purity figure higher than the work needs means paying for discarded material.
| Driver | Why it moves the figure | What to ask before committing |
|---|---|---|
| Residue count | More rounds of chemistry, more close by-products to remove | Whether a shorter fragment answers the same question |
| Aggregation-prone stretches | Incomplete coupling and deprotection; low yields even at modest length | Whether the maker has run anything like this sequence |
| Modifications and labels | Specialist building blocks and extra steps | How the modification will be confirmed, and at which position |
| Purity specification | Higher targets discard more product in purification | What purity the work needs, and how it will be measured |
| Scale and analysis | Larger runs and fuller test packages add instrument time | Which tests are included and which are extra |
Turnaround follows the same logic, with scheduling on top. Published lead times are commercial terms rather than properties of the chemistry, and we found no standard against which to judge them, so have the lead time, and what happens if it slips, written into the order.
The documentation to ask for on either route
The word doing the work here is specification. ICH Q7, the international guideline on manufacturing active pharmaceutical ingredients, defines one as “a list of tests, references to analytical procedures, and appropriate acceptance criteria” for those tests. That guideline states that it applies to ingredients for human drugs, and nothing here claims it governs a laboratory reagent; it is quoted because it is the clearest published statement of what a specification must contain to mean anything.
Read against that definition, a useful request is short. Ask for the sequence exactly as written, including termini and every modification by position; identity evidence, normally a mass spectrum; purity reported with the method that produced it rather than as a bare percentage; the salt and how much of the powder is peptide, since our guide to salt form and net peptide content explains why that figure changes a calculated concentration; and the lot number, checked against the vial.
A custom order adds one step: agree the acceptance criteria, and the consequence of missing them, before the run. The report will describe a batch that did not exist when you committed, so the specification is all that stands between your expectations and the result.
Lot-to-lot consistency on a long project
Two batches of the same sequence can meet the same purity figure and still differ. ICH Q7 describes an impurity profile as “a description of the identified and unidentified impurities present in an API”; a purity number compresses that description into one figure, and two lots agreeing on the number can disagree about the remainder.
Three habits remove the variable. Cover the study from one batch where you can, which is a sizing question at the start rather than a rescue later — our guide to ordering larger quantities covers how to size it. Record the lot against every experiment, so an unexpected shift can be traced instead of argued about. And when a change of batch is unavoidable, run the old and the new side by side in one assay before switching.
Neither route removes the problem: a repeat custom order is a new batch with its own profile, and a catalogue listing may hold more than one batch at once. The question is the same either way — can the whole study come from one lot, and will that lot’s report still be obtainable later?
What’s established and what isn’t
Established, and citable
- Solid-phase synthesis, published by Merrifield in 1963, underlies both routes.
- Fmoc chemistry is the method of choice, its building blocks made inexpensive by manufacturing scale (Behrendt et al., 2016).
- Poorly solvated chains aggregate on the resin, blocking complete coupling and deprotection; a 4% yield is cited for a hydrophobic 34-residue fragment in one solvent, improving to 12% in another (Mueller et al., 2020).
- Difficult sequences are a recognized subfield with dedicated methodology (Paradís-Bas et al., 2016; Coin et al., 2007).
- Purity and yield cannot both be maximized in batch chromatography, and impurities can differ from the target by one amino acid (De Luca et al., 2021).
- A specification is a list of tests, procedures and acceptance criteria; an impurity profile describes identified and unidentified impurities (ICH Q7).
- Stable-isotope-labelled peptides serve as internal standards (Gerber et al., 2003), and fluorescent labels can themselves interact with lipid bilayers (Hughes et al., 2014).
Open, or outside what the sourcing route can settle
- What a given synthesis should cost. Published figures are commercial terms tied to a specification, and we found no neutral benchmark for comparison.
- How long a custom order takes. Turnaround depends on scheduling and difficulty, not on a standard, so it belongs in writing in the order.
- Whether a custom batch will be purer than a stock lot. The chemistry and the purification decide that; the report shows it.
- Whether a listed peptide suits your assay. A catalogue entry describes a molecule, not its behaviour in your system.
- Which impurities sit behind a purity figure, and whether a maker has made a difficult sequence before — unless the report says, or you ask.
Sourcing from inside Canada
Start by checking whether the molecule is already listed in the form you need; that answer decides everything downstream. Read a listing as a specification rather than a product name: the sequence, the termini, whether it is a single compound or a blend, and which salt it is supplied as. If the sequence is standard and the form matches, the catalogue route removes the scheduling risk, and material priced in Canadian dollars and shipped from inside the country shortens the gap between decision and bench.
If what you need is not listed, or the quantity is not obviously covered, ask rather than assume: our contact page is the route for asking what can be supplied and what paperwork comes with it. Nothing here is an offer of custom synthesis, and whatever any supplier tells you informally about specification, quantity or timing is worth having in writing before an order is placed.
When a catalogue peptide will do
If a stock sequence fits your experiment, these research peptides ship from our Canadian catalogue, and their Janoshik test reports are listed on our Lab Testing page, so you can read them before you commit.
BPC-15715-amino-acid research peptideView product
GHK-CuCopper tripeptideView product
TB-500Thymosin beta-4 research peptideView product
KPVLys-Pro-Val tripeptideView productResearch use only. Pure Peptides Canada products are laboratory reagents for in-vitro research, not for human or veterinary use. This article explains how synthetic peptides are sourced and documented for education; it is not medical, dietary or dosing guidance, and it is not legal or regulatory advice.
Frequently asked questions
What is the difference between custom and catalogue peptides?
A catalogue peptide already exists: it was made to the supplier’s own specification and released against a report for that batch. A custom peptide is made after you order it, to a sequence, form, quantity and acceptance criteria you define. The chemistry is usually the same solid-phase method either way; what differs is who wrote the specification, and whether you can read the batch report before committing.
When do you actually need custom peptide synthesis?
Four honest cases: the sequence or form is not stocked anywhere, such as a novel analogue or a cyclized version; you need a site-specific modification or label, such as phosphorylation at a named residue, biotin or a stable isotope; you need a matched control peptide, such as a scrambled or alanine-substituted analogue; or you need a defined quantity from one batch.
Why does peptide synthesis cost more for longer sequences?
Every residue adds another round of coupling and deprotection, and the proportion of chains coming through each round intact falls as the chain grows. That means more starting material and a harder final separation, because the by-products hardest to remove are the ones closest to the target. Length is not the whole story: a short sequence that aggregates on the resin can cost more than a longer, well-behaved one.
How long does custom peptide synthesis take?
There is no standard answer, and anyone quoting one is describing their own commercial terms rather than a property of the chemistry. The schedule is the maker’s queue, plus one round of chemistry per residue, plus purification and analysis, and difficult sequences extend all three. Have the lead time, and what happens if it slips, written into the order.
What documents should come with a synthetic peptide?
The sequence exactly as written, including termini and every modification by position; identity evidence, normally a mass spectrum; purity reported with the method that produced it; the salt form and how much of the powder is peptide; and a lot number matching the vial. ICH Q7, a drug-manufacturing guideline, defines a specification as a list of tests, analytical procedures and acceptance criteria — a useful yardstick, though it does not settle what applies to a reagent.
Start with the catalogue
If your sequence is a standard research peptide, it may already be listed. Questions about a listing’s documentation? Ask us.
References
- Merrifield RB. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. J Am Chem Soc. 1963;85(14):2149–2154. DOI
- Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4–27. DOI
- Mueller LK, Baumruck AC, Zhdanova H, Tietze AA. Challenges and Perspectives in Chemical Synthesis of Highly Hydrophobic Peptides. Front Bioeng Biotechnol. 2020;8:162. Frontiers
- Paradís-Bas M, Tulla-Puche J, Albericio F. The road to the synthesis of “difficult peptides”. Chem Soc Rev. 2016;45(3):631–654. DOI
- Coin I, Beyermann M, Bienert M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat Protoc. 2007;2(12):3247–3256. DOI
- De Luca C, Lievore G, Bozza D, et al. Downstream Processing of Therapeutic Peptides by Means of Preparative Liquid Chromatography. Molecules. 2021;26(15):4688. MDPI
- International Council for Harmonisation. ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, Section 20 Glossary (Specification; Impurity Profile) and Section 1.3 Scope. Step 5, CPMP/ICH/4106/00, 2000. European Medicines Agency
- Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci USA. 2003;100(12):6940–6945. DOI
- Hughes LD, Rawle RJ, Boxer SG. Choose Your Label Wisely: Water-Soluble Fluorophores Often Interact with Lipid Bilayers. PLoS One. 2014;9(2):e87649. DOI
- Cunningham BC, Wells JA. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science. 1989;244(4908):1081–1085. DOI
- Vadukul DM, Gbajumo O, Marshall KE, Serpell LC. Amyloidogenicity and toxicity of the reverse and scrambled variants of amyloid-β 1–42. FEBS Lett. 2017;591(5):822–830. DOI
For laboratory research use only. Not for human or veterinary use. This article summarizes published scientific and standards material for educational purposes and is not medical, legal or regulatory advice.